Aaron Goldman

Aaron Goldman serves as an Operating Partner at BroadOak Capital Partners, focusing on investments and value creation in biotools and translational technologies for drug development. As a Faculty Instructor in Medicine and Director at Harvard Medical School since 2011, Aaron also holds various advisory roles, including Board Advisor at Xsphera Biosciences Inc. and Scientific Advisory Board Member at Celularity Inc. Additionally, Aaron acts as a Legislative Ambassador for the American Cancer Society Cancer Action Network. Previous roles include Senior Director of Translational Research at Ovid Therapeutics and Co-Founder of Transporter Therapeutics, where significant milestones included leading a $200 million deal with AstraZeneca. Aaron’s educational background encompasses a Ph.D. in Cancer Biology from the University of Arizona and post-doctoral training in Translational Medicine and Bioengineering at Harvard Medical School.